Advertisement
Screener

INHIBRX BIOSCIENCES, INC. (INBX) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

INHIBRX BIOSCIENCES, INC. Cash Flow Breakdown

Cash flow breakdown shows where INHIBRX BIOSCIENCES, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $129.79M went out.
  • Fiscal year ended 2025-12-31: from investing, $28.00K went out.
  • Fiscal year ended 2025-12-31: from financing, $101.45M came in.
  • Fiscal year ended 2025-12-31: change in cash, $28.38M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$129.79M-$28.00K$1.61M$99.84M*-$28.38M
2024-12-31-$194.41M-$2.60M$71.68M-$125.33M
2023-12-31-$193.31M-$4.59M$2.32M$199.65M*$4.06M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$29.92M*$0.00*$1.60M*
2026-03-31-$38.03M$0.00$471.00K$74.99M*$37.44M
2025-12-31-$30.12M*$0.00*$1.25M*
2025-09-30-$33.82M*-$7.00K*$352.00K*
2025-06-30-$29.95M*$0.00*$0.00*
2025-03-31-$35.90M-$21.00K$0.00$99.84M*$63.92M
2024-12-31-$43.72M*-$16.00K*$0.00*
2024-09-30-$30.28M*-$247.00K*$0.00*
2024-06-30-$57.36M*-$1.22M*$32.95M*
2024-03-31-$63.05M-$1.12M$38.73M-$25.44M
2023-12-31-$56.82M*-$3.44M*$1.08M*
2023-09-30-$54.24M*-$811.00K*$21.00K*$199.87M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Immunocore Holdings plc (IMCR)$1.613B-90.43
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81